Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Addressing the Unmet Needs of Patients with Acute Hepatic Porphyria

Premiere Date: Monday, October 3, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, October 3, 2023
Note: Credit Is No Longer Available


Brendan M. McGuire, MD, MSBrendan M. McGuire, MD, MS 
Professor of Medicine
Medical Director of Liver Transplantation
University of Alabama at Birmingham (UAB)
Birmingham, AL

Manish Thapar, MD, FACG, FAASLDManish Thapar, MD, FACG, FAASLD 
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA

Statement of Need

Acute hepatic porphyria (AHP) is a group of rare metabolic defects caused by inherited deficiencies in the heme biosynthetic pathway, leading to accumulations of porphyrin precursors. AHP is characterized by intensely painful attacks that can be life-threatening if incorrectly diagnosed. Nearly 80% of patients with AHP are females between the ages of 20 and 50. Treatment choices in acute attacks are limited, and historically, liver transplantation was the only curative option. Standard therapy includes supportive measures and intravenous hemin administration. Recently, subcutaneous administration of small interfering RNA (siRNA) targeting ALA synthase 1 (ALAS1) has been approved to treat AHP. This novel approach suppresses acute attacks and hemin usage.

Because of their key role in managing AHP, it is critical that clinicians involved in hematology stay current with best practices for managing this complex and often confusing disease. In this activity, experts in AHP provide practical and patient-centered guidance for optimizing screening, diagnosis, and treatment.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Relate disease etiology and pathophysiology to clinical manifestations of AHP.
  • Apply diagnostic resources to identify and confirm a diagnosis of AHP.
  • Integrate novel therapies in the management of AHP.
  • Implement long-term strategies to manage and minimize disease burden in patients with AHP.

Financial Support

Supported by an educational grant from Alnylam Pharmaceuticals, Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in hematology, oncology and/or primary care.

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring Material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. McGuire reports the following financial relationships:

Advisory Board: Mitsubishi Tanabe Pharma

Research Support: Alnylam Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Disc Medicine; and Grifols, S.A.

Dr. Thapar reports the following financial relationships:

Advisory Board: Alnylam Pharmaceuticals, Inc.; Disc Medicine; Mitsubishi Tanabe Pharma; and Recordati Rare Diseases

Research Support: Alnylam Pharmaceuticals, Inc.; and Mitsubishi Tanabe Pharma

Speakers Bureau: Alnylam Pharmaceuticals, Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Thomas Mitchell (planning committee)
  • Warren Beckman (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download